TY - JOUR
T1 - Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults
T2 - a collaborative study in Finland, the Netherlands, and the United Kingdom
AU - Versteegen, Pauline
AU - Pinto, Marta Valente
AU - Barkoff, Alex M.
AU - van Gageldonk, Pieter G.M.
AU - Kassteele, Jan van de
AU - van Houten, Marlies A.
AU - Sanders, Elisabeth A.M.
AU - de Groot, Ronald
AU - Diavatopoulos, Dimitri A.
AU - Bibi, Sagida
AU - Luoto, Raakel
AU - He, Qiushui
AU - Buisman, Anne Marie
AU - Kelly, Dominic F.
AU - Mertsola, Jussi
AU - Berbers, Guy A.M.
N1 - Funding Information:
We thank all participants who made this work possible, and all study nurses and clinical trial staff, especially Jacqueline Zonneveld and Greetje van Asselts, at the Spaarne Gasthuis Hospital, Hoofddorp, Netherlands for their help in the management of clinical data and performing home visits. We are also grateful to Inge Pronk and Eleonora Lambert, who both work at the Centre for Infectious Disease Control, for their assistance in clinical trial management. PERISCOPE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115910. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and BMGF. DFK receives salary from support from the NIHR Oxford Biomedical Research Centre. Individual participant data that underlie the results reported in this article, have been de-identified and deposited in the central database of the PERISCOPE Consortium and can be accessed by a request to the PERISCOPE management team. GAMB, DFK, and JM designed the trial with input from QH, EAMS, RdG, DAD, A-MB, PV, MVP, and AMB. Trial coordination, clinical trial management and clinical data collection was performed by PV, MVP, AMB, MAvH, RL, and SB. Samples were processed by PGMvG, SB, MVP, AMB and PV. Luminex data were generated by PGMvG and PV. Underlying data were verified by PV, PGMvG, GAMB, DFK, JM. Data analysis was performed by JvdK with input from PV, GAMB, DFK, and JM. PV and GAMB wrote the first draft of the manuscript and all co-authors contributed to subsequent drafts. All authors read and approved the final manuscript. Funding: PERISCOPE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115910. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme, EFPIA and BMGF.
Funding Information:
Funding: PERISCOPE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115910. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme, EFPIA and BMGF.
Funding Information:
PERISCOPE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115910. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and BMGF.
Funding Information:
DFK receives salary from support from the NIHR Oxford Biomedical Research Centre.
Publisher Copyright:
© 2021 The Authors
PY - 2021/3
Y1 - 2021/3
N2 - Background: Pertussis can lead to serious disease and even death in infants. Older adults are more vulnerable to complications as well. In high-income countries, acellular pertussis vaccines are used for priming vaccination. In the administration of booster vaccinations to different age groups and target populations there is a substantial between-country variation. We investigated the effect of age on the response to acellular pertussis booster vaccination in three European countries. Methods: This phase IV longitudinal intervention study performed in Finland, the Netherlands and the United Kingdom between October 2017 and January 2019 compared the vaccine responses between healthy participants of four age groups: children (7–10y), adolescents (11–15y), young adults (20–34y), and older adults (60–70y). All participants received a three-component acellular pertussis vaccine. Serum IgG and IgA antibody concentrations to pertussis antigens at day 0, 28, and 1 year were measured with a multiplex immunoassay, using pertussis toxin concentrations at day 28 as primary outcome. This trial is registered with ClinicalTrialsRegister.eu (2016–003,678–42). Findings: Children (n = 109), adolescents (n = 121), young adults (n = 74), and older adults (n = 75) showed high IgG antibody concentrations to pertussis toxin at day 28 with GMCs of 147 (95% CI 120–181), 161 (95% CI 132–196), 103 (95% CI 80–133), and 121 IU/ml (95% CI 94–155), respectively. A significant increase in GMCs for vaccine antigens in all age groups by 28 days was found which had decreased by 1 year. Differences in patterns of IgG GMCs at 28 days and 1 year post-vaccination did not have a consistent relationship to age. In contrast, IgA antibodies for all antigens increased with age at all timepoints. Interpretation: Acellular pertussis booster vaccination induces significant serum IgG responses to pertussis antigens across the age range which are not uniformly less in older adults. Acellular boosters could be considered for older adults to reduce the health and economic burden of pertussis.
AB - Background: Pertussis can lead to serious disease and even death in infants. Older adults are more vulnerable to complications as well. In high-income countries, acellular pertussis vaccines are used for priming vaccination. In the administration of booster vaccinations to different age groups and target populations there is a substantial between-country variation. We investigated the effect of age on the response to acellular pertussis booster vaccination in three European countries. Methods: This phase IV longitudinal intervention study performed in Finland, the Netherlands and the United Kingdom between October 2017 and January 2019 compared the vaccine responses between healthy participants of four age groups: children (7–10y), adolescents (11–15y), young adults (20–34y), and older adults (60–70y). All participants received a three-component acellular pertussis vaccine. Serum IgG and IgA antibody concentrations to pertussis antigens at day 0, 28, and 1 year were measured with a multiplex immunoassay, using pertussis toxin concentrations at day 28 as primary outcome. This trial is registered with ClinicalTrialsRegister.eu (2016–003,678–42). Findings: Children (n = 109), adolescents (n = 121), young adults (n = 74), and older adults (n = 75) showed high IgG antibody concentrations to pertussis toxin at day 28 with GMCs of 147 (95% CI 120–181), 161 (95% CI 132–196), 103 (95% CI 80–133), and 121 IU/ml (95% CI 94–155), respectively. A significant increase in GMCs for vaccine antigens in all age groups by 28 days was found which had decreased by 1 year. Differences in patterns of IgG GMCs at 28 days and 1 year post-vaccination did not have a consistent relationship to age. In contrast, IgA antibodies for all antigens increased with age at all timepoints. Interpretation: Acellular pertussis booster vaccination induces significant serum IgG responses to pertussis antigens across the age range which are not uniformly less in older adults. Acellular boosters could be considered for older adults to reduce the health and economic burden of pertussis.
KW - Adults
KW - Children
KW - IgA
KW - IGG
KW - Pertussis
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85101528570&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2021.103247
DO - 10.1016/j.ebiom.2021.103247
M3 - Article
C2 - 33647770
AN - SCOPUS:85101528570
SN - 2352-3964
VL - 65
JO - EBioMedicine
JF - EBioMedicine
M1 - 103247
ER -